AstraZeneca: Enhertu Phase 2 Trial Meets Primary Endpoint

Date : 01/27/2020 @ 7:58AM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 44.835  0.985 (2.25%) @ 5:40PM

AstraZeneca: Enhertu Phase 2 Trial Meets Primary Endpoint

Astrazeneca (LSE:AZN)
Historical Stock Chart

3 Months : From Jan 2020 to Apr 2020

Click Here for more Astrazeneca Charts.

By Anthony O. Goriainoff


AstraZeneca PLC (AZN.LN) said on Monday that the Phase 2 trial for Enhertu, its gastric cancer drug, met its primary endpoint.

The U.K. pharmaceutical company said the trial met the primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2-positive metastatic gastric cancer compared to an investigator's choice of chemotherapy.

"Given the previous results seen in our HER2-positive development program and now in HER2-positive metastatic gastric cancer, we believe this antibody drug conjugate has the potential to redefine the treatment of patients with HER2-expressing cancers," the company said.


Write to Anthony O. Goriainoff at


(END) Dow Jones Newswires

January 27, 2020 02:43 ET (07:43 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.